Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer

Jan OHOTSKI, Joanne Edwards, Beatrix Elsberger, Carol Watson, Clare Orange, Elizabeth Mallon, Susan Pyne, Nigel Pyne

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Sphingosine kinase is an enzyme that catalyses the phosphorylation of sphingosine to form sphingosine 1-phosphate. Sphingosine 1-phosphate is a bioactive lipid, which has been shown to have an important role in promoting the survival, growth and invasiveness of cancer cells. Sphingosine 1-phosphate binds to five different plasma membrane sphingosine 1-phosphate receptors (S1P1–5) and can regulate intracellular target proteins. We have used immunohistochemical analysis to determine the concurrent expression levels of sphingosine kinase 1 or S1P receptors and other signaling proteins in estrogen receptor-positive breast cancer tumors and have then assessed the impact of these combinations on clinical outcome. This approach has enabled identification of (i) novel biomarkers and (ii) several spatially controlled associations between either sphingosine kinase 1 or S1P1–3 and other signaling proteins whose combination affect prognosis. For instance, the translocation of sphingosine kinase 1 to the plasma membrane has been shown to be a critical determinant in cancer progression. However, our findings identify an additional novel role for the nuclear localization of sphingosine kinase 1 combined with either ERK-1/2 or SFK or LYN or AKT or NF-κB, which significantly shortens disease-specific survival and/or recurrence. We also demonstrate that nuclear S1P2 receptor and c-SRC are associated with improved prognosis and this is linked with a reduction in the nuclear localization of sphingosine kinase 1. These findings identify potential novel biomarker associations, which might serve as new targets for drug intervention designed to improve treatment of estrogen receptor-positive breast cancer.
LanguageEnglish
Pages605–616
Number of pages12
JournalInternational Journal of Cancer
Volume132
Issue number3
Early online date1 Feb 2012
DOIs
Publication statusPublished - 1 Feb 2013

Fingerprint

Lysosphingolipid Receptors
Estrogen Receptors
Breast Neoplasms
Proteins
Biomarkers
Cell Membrane
Sphingosine
Cytoplasmic and Nuclear Receptors
sphingosine kinase
Neoplasms
Phosphorylation
Lipids
Recurrence
Enzymes
Growth
Pharmaceutical Preparations
sphingosine 1-phosphate

Keywords

  • sphingosine 1-phosphate
  • sphingosine kinase
  • sphingosine 1-phosphate receptor
  • extracellular signal regulated kinase
  • C-RAF
  • src-family kinases
  • NF-kappa B
  • AKT
  • disease-specific survival
  • disease recurrence
  • estrogen receptor-positive breast cancer

Cite this

@article{61f92ac225834c98bd7ab0ac384788a4,
title = "Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer",
abstract = "Sphingosine kinase is an enzyme that catalyses the phosphorylation of sphingosine to form sphingosine 1-phosphate. Sphingosine 1-phosphate is a bioactive lipid, which has been shown to have an important role in promoting the survival, growth and invasiveness of cancer cells. Sphingosine 1-phosphate binds to five different plasma membrane sphingosine 1-phosphate receptors (S1P1–5) and can regulate intracellular target proteins. We have used immunohistochemical analysis to determine the concurrent expression levels of sphingosine kinase 1 or S1P receptors and other signaling proteins in estrogen receptor-positive breast cancer tumors and have then assessed the impact of these combinations on clinical outcome. This approach has enabled identification of (i) novel biomarkers and (ii) several spatially controlled associations between either sphingosine kinase 1 or S1P1–3 and other signaling proteins whose combination affect prognosis. For instance, the translocation of sphingosine kinase 1 to the plasma membrane has been shown to be a critical determinant in cancer progression. However, our findings identify an additional novel role for the nuclear localization of sphingosine kinase 1 combined with either ERK-1/2 or SFK or LYN or AKT or NF-κB, which significantly shortens disease-specific survival and/or recurrence. We also demonstrate that nuclear S1P2 receptor and c-SRC are associated with improved prognosis and this is linked with a reduction in the nuclear localization of sphingosine kinase 1. These findings identify potential novel biomarker associations, which might serve as new targets for drug intervention designed to improve treatment of estrogen receptor-positive breast cancer.",
keywords = "sphingosine 1-phosphate, sphingosine kinase, sphingosine 1-phosphate receptor, extracellular signal regulated kinase, C-RAF, src-family kinases, NF-kappa B, AKT, disease-specific survival, disease recurrence, estrogen receptor-positive breast cancer",
author = "Jan OHOTSKI and Joanne Edwards and Beatrix Elsberger and Carol Watson and Clare Orange and Elizabeth Mallon and Susan Pyne and Nigel Pyne",
year = "2013",
month = "2",
day = "1",
doi = "10.1002/ijc.27692",
language = "English",
volume = "132",
pages = "605–616",
journal = "International Journal of Cancer",
issn = "0020-7136",
number = "3",

}

Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer. / OHOTSKI, Jan; Edwards, Joanne; Elsberger, Beatrix; Watson, Carol; Orange, Clare; Mallon, Elizabeth; Pyne, Susan; Pyne, Nigel.

In: International Journal of Cancer, Vol. 132, No. 3, 01.02.2013, p. 605–616.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer

AU - OHOTSKI, Jan

AU - Edwards, Joanne

AU - Elsberger, Beatrix

AU - Watson, Carol

AU - Orange, Clare

AU - Mallon, Elizabeth

AU - Pyne, Susan

AU - Pyne, Nigel

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Sphingosine kinase is an enzyme that catalyses the phosphorylation of sphingosine to form sphingosine 1-phosphate. Sphingosine 1-phosphate is a bioactive lipid, which has been shown to have an important role in promoting the survival, growth and invasiveness of cancer cells. Sphingosine 1-phosphate binds to five different plasma membrane sphingosine 1-phosphate receptors (S1P1–5) and can regulate intracellular target proteins. We have used immunohistochemical analysis to determine the concurrent expression levels of sphingosine kinase 1 or S1P receptors and other signaling proteins in estrogen receptor-positive breast cancer tumors and have then assessed the impact of these combinations on clinical outcome. This approach has enabled identification of (i) novel biomarkers and (ii) several spatially controlled associations between either sphingosine kinase 1 or S1P1–3 and other signaling proteins whose combination affect prognosis. For instance, the translocation of sphingosine kinase 1 to the plasma membrane has been shown to be a critical determinant in cancer progression. However, our findings identify an additional novel role for the nuclear localization of sphingosine kinase 1 combined with either ERK-1/2 or SFK or LYN or AKT or NF-κB, which significantly shortens disease-specific survival and/or recurrence. We also demonstrate that nuclear S1P2 receptor and c-SRC are associated with improved prognosis and this is linked with a reduction in the nuclear localization of sphingosine kinase 1. These findings identify potential novel biomarker associations, which might serve as new targets for drug intervention designed to improve treatment of estrogen receptor-positive breast cancer.

AB - Sphingosine kinase is an enzyme that catalyses the phosphorylation of sphingosine to form sphingosine 1-phosphate. Sphingosine 1-phosphate is a bioactive lipid, which has been shown to have an important role in promoting the survival, growth and invasiveness of cancer cells. Sphingosine 1-phosphate binds to five different plasma membrane sphingosine 1-phosphate receptors (S1P1–5) and can regulate intracellular target proteins. We have used immunohistochemical analysis to determine the concurrent expression levels of sphingosine kinase 1 or S1P receptors and other signaling proteins in estrogen receptor-positive breast cancer tumors and have then assessed the impact of these combinations on clinical outcome. This approach has enabled identification of (i) novel biomarkers and (ii) several spatially controlled associations between either sphingosine kinase 1 or S1P1–3 and other signaling proteins whose combination affect prognosis. For instance, the translocation of sphingosine kinase 1 to the plasma membrane has been shown to be a critical determinant in cancer progression. However, our findings identify an additional novel role for the nuclear localization of sphingosine kinase 1 combined with either ERK-1/2 or SFK or LYN or AKT or NF-κB, which significantly shortens disease-specific survival and/or recurrence. We also demonstrate that nuclear S1P2 receptor and c-SRC are associated with improved prognosis and this is linked with a reduction in the nuclear localization of sphingosine kinase 1. These findings identify potential novel biomarker associations, which might serve as new targets for drug intervention designed to improve treatment of estrogen receptor-positive breast cancer.

KW - sphingosine 1-phosphate

KW - sphingosine kinase

KW - sphingosine 1-phosphate receptor

KW - extracellular signal regulated kinase

KW - C-RAF

KW - src-family kinases

KW - NF-kappa B

KW - AKT

KW - disease-specific survival

KW - disease recurrence

KW - estrogen receptor-positive breast cancer

UR - http://onlinelibrary.wiley.com/doi/10.1002/ijc.27692/abstract;jsessionid=229DE20E703B51E6030D4502851AAB8F.d03t02

U2 - 10.1002/ijc.27692

DO - 10.1002/ijc.27692

M3 - Article

VL - 132

SP - 605

EP - 616

JO - International Journal of Cancer

T2 - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -